Navigation Links
Success of Hepatitis C Drugs May Depend on Gene Variant
Date:6/13/2010

Researchers hope to identify patients for whom treatment will be ineffective

SATURDAY, June 12 (HealthDay News) -- A genetic variant associated with poor response to treatment for hepatitis C infection has been identified by scientists.

The researchers analyzed the DNA of 1,362 hepatitis C patients and pinpointed the variant in those who failed to respond to treatment. The variant occurs in a gene called IL28B, which encodes for the antiviral cytokine (cell-signaling) interferon lambda.

The study was to be presented Saturday at the annual conference of the European Society of Human Genetics.

Current treatment for hepatitis C includes a combination of an interferon and the antiviral medication ribavirin. Side effects are common and can be so serious that some people have to take time off work.

Identifying hepatitis C patients with this genetic variant could spare them from suffering side effects from a treatment that will provide them with little benefit, said the scientists at the University of Lausanne in Switzerland in a news release from the European Society of Human Genetics.

The research may also help in the development of new treatments, they said.

More information

The American Academy of Family Physicians has more about hepatitis C.



-- Robert Preidt



SOURCE: European Society of Human Genetics, news release, June 12, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Connecture, Inc. Launches New Technology Package to Increase Health Insurance Carriers' Success in the Online Individual Market
2. SIS Rules-Based Charging Solution Successfully Peer Reviewed by HFMA for Third Consecutive Year
3. Parabit Systems Successfully Installs Infant Protection Systems at Major Long Island Hospitals
4. Injections May Boost Knee Surgery Success
5. From Conflict to Consensus: Interaction Associates Outlines How Leaders Can Achieve Successful Alignment and Implementation
6. Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction
7. First successful use of expanded umbilical-cord blood units to treat leukemia
8. Race, Weight May Influence Success of Prostate Surgery
9. Allegheny Medical Achieves Remarkable Success with Their Fibromyalgia Flow Care Plan
10. AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign
11. Local Businesses Team with Success 4 Kids & Families to Provide Holiday Gifts and Meals for Needy Families
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Success of Hepatitis C Drugs May Depend on Gene Variant
(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress ... Onnit brain and mood optimization products to the store is just one more ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
Breaking Medicine Technology: